Literature DB >> 17596352

Comparison of the abbott 7000 and bayer 340 systems for measurement of hepatitis C virus load.

Helene C Highbarger1, Zonghui Hu, Shyam Kottilil, Julia A Metcalf, Michael A Polis, M B Vasudevachari, H Clifford Lane, Robin L Dewar.   

Abstract

This study compared two commercially available assays for the measurement of hepatitis C virus (HCV) RNA levels, the Bayer HCV RNA (version 3.0) branched DNA assay and the Abbott HCV analyte-specific reagent real-time PCR assay, to assess their quantitative relationships, ease of performance, and time to completion. The study group consisted of randomly selected patients from the NIAID human immunodeficiency virus (HIV) outpatient clinic who were infected with HIV type 1 and HCV. One hundred eighty-four samples from 66 patients coinfected with HIV and HCV receiving treatments under various protocols were analyzed for the correlation and agreement of the results. The results indicated that the two assays correlate well in the overlapping linear ranges of the assays and show good agreement. From the results obtained, we have derived a mathematical formula to compare the viral load results between the two assays, which is given as log(10) Abbott assay measure = 0.032 + 1.01 log(10) Bayer assay measure. Although it is preferable to use the same quantitation assay throughout the course of a patient's treatment, valid comparisons of the HCV RNA levels may be made between the results obtained by either of these assays in the overlapping linear range (615 to 7,700,000 IU/ml).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596352      PMCID: PMC2045268          DOI: 10.1128/JCM.00202-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Multiple outputation: inference for complex clustered data by averaging analyses from independent data.

Authors:  Dean Follmann; Michael Proschan; Eric Leifer
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

2.  Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay.

Authors:  R S Ross; S Viazov; S Sarr; S Hoffmann; A Kramer; M Roggendorf
Journal:  J Virol Methods       Date:  2002-03       Impact factor: 2.014

3.  The effect of storage at different temperatures on the stability of Hepatitis C virus RNA in plasma samples.

Authors:  Marta José; Sònia Curtu; Rodrigo Gajardo; Juan I Jorquera
Journal:  Biologicals       Date:  2003-03       Impact factor: 1.856

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  The stability of hepatitis C virus RNA after storage at +4 degrees C.

Authors:  G Gessoni; P Barin; A Frigato; M Fezzi; G de Fusco; N Arreghini; P Galli; G Marchiori
Journal:  J Viral Hepat       Date:  2000-07       Impact factor: 3.728

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.

Authors:  Pascale Trimoulet; Victor de Lédinghen; Juliette Foucher; Laurent Castéra; Hervé Fleury; Patrice Couzigou
Journal:  J Med Virol       Date:  2004-01       Impact factor: 2.327

10.  Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice.

Authors:  Mitchell L Shiffman; Andrea Ferreira-Gonzalez; K Rajender Reddy; Richard K Sterling; Velimir A Luketic; R Todd Stravitz; Arun J Sanyal; Carleton T Garrett; Maria De Medina; Eugene R Schiff
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  2 in total

1.  Within-Cluster Resampling for Analysis of Family Data: Ready for Prime-Time?

Authors:  Hemant K Tiwari; Amit Patki; David B Allison
Journal:  Stat Interface       Date:  2010-04-01       Impact factor: 0.582

2.  A novel diagnostic target in the hepatitis C virus genome.

Authors:  Jan Felix Drexler; Bernd Kupfer; Nadine Petersen; Rejane Maria Tommasini Grotto; Silvia Maria Corvino Rodrigues; Klaus Grywna; Marcus Panning; Augustina Annan; Giovanni Faria Silva; Jill Douglas; Evelyn S C Koay; Heidi Smuts; Eduardo M Netto; Peter Simmonds; Maria Inês de Moura Campos Pardini; W Kurt Roth; Christian Drosten
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.